Literature for LY411575 (A22.001 inhibitor)

(Topics flags: I Inhibitor. To select only the references relevant to a single topic, click the link above. See explanation.)

2008
1. Abramowski,D., Wiederhold,K.H., Furrer,U., Jaton,A.L., Neuenschwander,A., Runser,M.J., Danner,S., Reichwald,J., Ammaturo,D., Staab,D., Stoeckli,M., Rueeger,H., Neumann,U. and Staufenbiel,M.
   Dynamics of Abeta turnover and deposition in different beta-amyloid precursor protein transgenic mouse models following gamma-secretase inhibition
   J Pharmacol Exp Ther327, 411-424. PubMed  Europe PubMed DOI  I
2007
2. Fuwa,H., Takahashi,Y., Konno,Y., Watanabe,N., Miyashita,H., Sasaki,M., Natsugari,H., Kan,T., Fukuyama,T., Tomita,T. and Iwatsubo,T.
   Divergent synthesis of multifunctional molecular probes to elucidate the enzyme specificity of dipeptidic gamma-secretase inhibitors
   ACS Chem Biol2, 408-418. PubMed  Europe PubMed DOI  I
3. Peters,J.U., Galley,G., Jacobsen,H., Czech,C., David-Pierson,P., Kitas,E.A. and Ozmen,L.
   Novel orally active, dibenzazepinone-based gamma-secretase inhibitors
   Bioorg Med Chem Lett17, 5918-5923. PubMed  Europe PubMed DOI  I
2006
4. [YEAR:15-4-2006]Dev,K.K., Chatterjee,S., Osinde,M., Stauffer,D., Morgan,H., Kobialko,M., Dengler,U., Rueeger,H., Martoglio,B. and Rovelli,G.
   Signal peptide peptidase dependent cleavage of type II transmembrane substrates releases intracellular and extracellular signals
   Eur J Pharmacol540, 10-17. PubMed  Europe PubMed DOI  I
2005
5. [YEAR:2-3-2005]Best,J.D., Jay,M.T., Otu,F., Ma,J., Nadin,A., Ellis,S., Lewis,H.D., Pattison,C., Reilly,M., Harrison,T., Shearman,M.S., Williamson,T.L. and Atack,J.R.
   Quantitative measurement of changes in amyloid-beta(40) in the rat brain and cerebrospinal fluid following treatment with the gamma-secretase inhibitor LY-411575 [N2-[(2S)-2-(3,5-difluorophenyl)-2-hydroxyethanoyl]-N1-[(7S)-5-methyl-6-ox o-6,7-dihydro-5H-dibenzo[b,d]azepin-7-yl]-L-alaninamide]
   J Pharmacol Exp Ther313, 902-908. PubMed  Europe PubMed DOI  I
2004
6. [YEAR:12-1-2004]Lanz,T.A., Hosley,J.D., Adams,W.J. and Merchant,K.M.
   Studies of Abeta pharmacodynamics in the brain, cerebrospinal fluid, and plasma in young (plaque-free) Tg2576 mice using the gamma-secretase inhibitor N2-[(2S)-2-(3,5-difluorophenyl)-2-hydroxyethanoyl]-N1-[(7S)-5-methyl-6-oxo -6,7-dihydro-5H-dibenzo[b,d]azepin-7-yl]-L-alaninamide (LY-411575)
   J Pharmacol Exp Ther309, 49-55. PubMed  Europe PubMed DOI  I
7. [YEAR:6-1-2004]Wong,G.T., Manfra,D., Poulet,F.M., Zhang,Q., Josien,H., Bara,T., Engstrom,L., Pinzon-Ortiz,M., Fine,J.S., Lee,H.J., Zhang,L., Higgins,G.A. and Parker,E.M.
   Chronic treatment with the gamma-secretase inhibitor LY-411,575 inhibits beta-amyloid peptide production and alters lymphopoiesis and intestinal cell differentiation
   J Biol Chem279, 12876-12882. PubMed  Europe PubMed DOI  I